FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
1. FDA approved Gilead's lenacapavir for HIV prevention, a major milestone. 2. Lenacapavir is less frequent than current treatments, possibly increasing adherence. 3. Proposed funding cuts to HIV programs pose a significant threat to access. 4. Gilead plans accessible pricing and global supply commitments for lenacapavir. 5. Stigma around HIV may hinder lenacapavir's uptake in diverse communities.